Pharmaceutical - Nephrology and Hepatology

Filter

Current filters:

Nephrology and Hepatology

Popular Filters

1 to 25 of 88 results

Bristol-Myers Squibb launches Daklinza in the UK for chronic hepatitis C

Bristol-Myers Squibb launches Daklinza in the UK for chronic hepatitis C

03-09-2014

US drug major Bristol-Myers Squibb has launched Daklinza (daclastavir) in the UK for chronic hepatitis…

AntiviralsBristol-Myers SquibbDaklinzaHepatitis CNephrology and HepatologyPharmaceuticalRegulationUK

AstraZeneca and Mitsubishi Tanabe Pharma to collaborate on diabetic nephropathy

AstraZeneca and Mitsubishi Tanabe Pharma to collaborate on diabetic nephropathy

20-08-2014

Anglo-Swedish drug major AstraZeneca has entered into a three-year research collaboration on diabetic…

AstraZenecaChronic kidney diseaseDiabetesJapanKidney diseasesMitsubishi TanabeNephrology and HepatologyPharmaceuticalResearchSweden

Intercept shares rocket on positive liver drug results

Intercept shares rocket on positive liver drug results

12-08-2014

Shares of US drug developer Intercept Pharmaceuticals leapt 53% to $358.07 in after-hours trading on…

Intercept PharmaceuticalsLiver diseaseNephrology and Hepatologyobeticholic acidPharmaceuticalResearchUSA

OPKO’s Rayaldee Ph III trial meets primary endpoints in SHPT

12-08-2014

US drugmaker OPKO Health has released positive top-line results from the first pivotal Phase III trial…

Endocrine systemJoel MelnickNephrology and HepatologyOPKO HealthPharmaceuticalRayaldeeResearchUSAVitamin D

NICE issues new quality standard to prevent hepatitis B transmission

NICE issues new quality standard to prevent hepatitis B transmission

28-07-2014

On World Hepatitis Day today, the UK’s clinical standards body, the National Institute for Health and…

BaracludeBristol-Myers SquibbGilead SciencesHealthHepatitis BHepatologyMedicineNephrology and HepatologyPharmaceuticalPurinesRegulationUKViread

Veloxis and Chiesi receive approval from European Commission on anti-organ rejection drug

Veloxis and Chiesi receive approval from European Commission on anti-organ rejection drug

28-07-2014

Denmark-based Veloxis Pharmaceuticals and Italian company Chiesi Farmaceutici have said that the European…

Chiesi FarmaceuticiDenmarkEnvarsusEuropean CommissionItalyNephrology and HepatologyOrgan transplantsPharmaceuticalRegulationVeloxis Pharmaceuticals

Resverlogix’s RVX-208 reduces major adverse cardiovascular events in diabetes mellitus patients

Resverlogix’s RVX-208 reduces major adverse cardiovascular events in diabetes mellitus patients

23-07-2014

Canadian clinical-stage cardiovascular specialist Resverlogix Corp has announced results it believes…

CanadaCardio-vascularDiabetesNephrology and HepatologyPharmaceuticalResearchResverlogixRVX-208

Tesamorelin, which reduces abdominal fat in HIV patients, may also reduce fat in liver

22-07-2014

The only drug to receive US Food and Drug Administration approval for reduction of the abdominal fat…

EgriftaEMD SeronoMerck KGaANephrology and HepatologyPharmaceuticalResearchtesamorelinTherapy for HIVUSA

Amgen announces positive Phase III results for AMG 416 in kidney disease

Amgen announces positive Phase III results for AMG 416 in kidney disease

18-07-2014

USA-based Amgen, the world's leading independent biotech firm, has said its Phase III study evaluating…

AMG 416AmgenChronic kidney diseaseHyperparathyroidismNephrology and HepatologyPharmaceuticalResearchSecondary hyperparathyroidismUSA

Highlights of EMA Pharmacovigilance committee July meeting

Highlights of EMA Pharmacovigilance committee July meeting

14-07-2014

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) concluded two safety…

bromocriptineEuropeNephrology and HepatologyNeurologicalPharmaceuticalRegulationRiensoTakeda Pharmaceuticalvalproate Sodium InjectionWomen's Health

Astellas details pipeline progress at R&D meeting

Astellas details pipeline progress at R&D meeting

11-07-2014

Japanese drug major Astellas Pharmaceuticals outlined its research framework at its R&D meeting held…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesAstellas PharmaBetmigaisavuconazoleJapanNephrology and HepatologyOncologyPharmaceuticalroxadustatXtandi

US nephrologists view hyperphosphatemia treatment

US nephrologists view hyperphosphatemia treatment

11-07-2014

Surveyed nephrologists report awareness of the US Food and Drug Administration's approval of Vifor Fresenius…

AmgenFreseniusGlaxoSmithKlineLa Jolla PharmaceuticalMarkets & MarketingNephrology and HepatologyOPKO HealthPharmaceuticalRayaldeeSensiparUSAvelcalcetideVelphoroVenoferVifor Pharma

Mariel Therapeutics to acquire Stryker's BMP-7 assets

Mariel Therapeutics to acquire Stryker's BMP-7 assets

08-07-2014

US clinical-stage drug developer Mariel Therapeutics has entered into a definitive agreement to acquire…

Anti-Arthritics/RheumaticsMariel TherapeuticsMergers & AcquisitionsNephrology and HepatologyPharmaceuticalStryker Corp

Jazz Pharma gains Americas rights to defibrotide from Sigma-Tau

Jazz Pharma gains Americas rights to defibrotide from Sigma-Tau

02-07-2014

Ireland-headquartered drugmaker Jazz Pharmaceuticals has signed a definitive agreement Pharmaceuticals…

defibrotideGentiumJazz PharmaceuticalsLicensingNephrology and HepatologyNorth AmericaPharmaceuticalSigma-TauSouth America

Retrophin acquires US Thiola rights from Mission Pharmacal

Retrophin acquires US Thiola rights from Mission Pharmacal

30-05-2014

US drugmaker Retrophin has entered into a license agreement with Mission Pharmacal, a private company…

LicensingMission PharmacalNephrology and HepatologyPharmaceuticalRare diseasesRetrophinThiolaUSA

$25 million milestone for Ardelyx from tenapanor deal with AstraZeneca

15-05-2014

Closely-held US biopharma firm Ardelyx has received a $25 million milestone payment from Anglo-Swedish…

ArdelyxAstraZenecaLicensingNephrology and HepatologyPharmaceuticalResearchtenapanor

Obeticholic acid produces meaningful biochemical and clinical improvements in PBC cirrhosis patients

14-04-2014

Results from an international Phase III study presented at the European Association for the Study of…

Intercept PharmaceuticalsNephrology and Hepatologyobeticholic acidPharmaceuticalResearch

Otsuka’s Samsca, first ADPKD therapy, approved in Japan

25-03-2014

Japanese drugmaker Otsuka Pharmaceutical says it has become the first company in the world to obtain…

Asia-PacificJapanNephrology and HepatologyOtsukaPharmaceuticalRegulationSamsca

Strong Ph III data on Intercept’s OCA, but shares hit by side effect concerns

Strong Ph III data on Intercept’s OCA, but shares hit by side effect concerns

17-03-2014

USA-based Intercept Pharmaceuticals reported positive Phase III results on its obeticholic acid (OCA)…

Intercept PharmaceuticalsNephrology and Hepatologyobeticholic acidPharmaceuticalResearch

La Jolla’s shares soar as it reports positive results in kidney disease trial

12-03-2014

US-based La Jolla Pharmaceutical Company has announced positive top-line results from its randomized,…

La Jolla PharmaceuticalNephrology and HepatologyPharmaceuticalResearchUSA

Keryx Biopharma files for EU approval of Zerenex

Keryx Biopharma files for EU approval of Zerenex

10-03-2014

US drugmaker Keryx Biopharmaceuticals has submitted a Marketing Authorization Application to the European…

EuropeKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationZerenex

1 to 25 of 88 results

Back to top